Promontory Therapeutics to Present Research on PT-112 in Advanced Non-Small Cell Lung Cancer at the ESMO Immuno-Oncology Congress 2022

NEW YORK, Nov. 30, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will present clinical data on lead therapeutic candidate, PT-112, in combination with avelumab, and its immunogenic cell death inducing effects in patients with advanced non-small cell lung cancer as a poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2022 in Geneva, Switzerland, on Dec. 7-9.

Poster Session Details
Title: A phase 2a study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab ("PAVE") in advanced non-small cell lung cancer (NSCLC) patients (pts)
Presentation Number: 125P
Session location: Foyer ABC, Palexpo Exhibition Centre
Session time: Thursday, December 8, 2022, 12:30 p.m. to 1:15 p.m. CET
Speaker/Lead Author: Martina Imbimbo, MD, Lausanne University Hospital, Switzerland

Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022. Abstracts will also be published online in the ESMO-IO Congress 2022 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).

For more information about PT-112 and Promontory Therapeutics' clinical pipeline visit www.PromontoryTx.com.

PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents a highly potent inducer of this immunological form of cancer cell death. Further, PT-112 harbors a property known as osteotropism, or the propensity of the drug to reach its highest concentrations in certain areas of the bone, making it a candidate for treatment of patients with cancers that originate in, or metastasize to, the bone. The first in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The combination Phase 1b dose escalation study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress and the Phase 2a dose confirmation cohort in non-small cell lung cancer (NSCLC) patients will be reported at ESMO IO 2022. The Phase 1 study in patients with relapsed or refractory multiple myeloma presented at ASH is the third completed Phase 1 study of PT-112. Monotherapy Phase 2 development is ongoing in mCRPC, and now includes the Phase 2 proof of concept study in thymic epithelial tumors under the company's formal collaboration with the NCI.

Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy. The company's lead candidate, PT-112, is the first small molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to pattern recognition receptors on dendritic cells and promote the adaptive immune response in the tumor microenvironment. Clinical data generated across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company's research and development work has been conducted in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active Phase 2 trial underway with the NCI utilizing PT-112 in thymic epithelial tumors where PT-112 has received Orphan Drug designation.

To learn more about Promontory Therapeutics, visit the company's website here.

CONTACTS:

Promontory Therapeutics
Brooke Raphael, MS
VP, Strategy & Operations
Tel: +1 (646) 974-6453
Email: [email protected]

ICR Westwicke

Investors: 
Stephanie Carrington
Tel: +1 646 277 1282
Email: [email protected]

Media: 
Alexis Feinberg
Tel: +1 203-939-2225
Email: [email protected]

SOURCE Promontory Therapeutics Inc.